These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 9544200

  • 1. Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis.
    Lumma WC, Witherup KM, Tucker TJ, Brady SF, Sisko JT, Naylor-Olsen AM, Lewis SD, Lucas BJ, Vacca JP.
    J Med Chem; 1998 Mar 26; 41(7):1011-3. PubMed ID: 9544200
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitors.
    Isaacs RC, Newton CL, Cutrona KJ, Mercer SP, Payne LS, Stauffer KJ, Williams PD, Cook JJ, Krueger JA, Lewis SD, Lucas BJ, Lyle EA, Lynch JJ, McMasters DR, Naylor-Olsen AM, Michener MT, Wallace AA.
    Bioorg Med Chem Lett; 2011 Mar 01; 21(5):1536-40. PubMed ID: 21295467
    [Abstract] [Full Text] [Related]

  • 3. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
    Isaacs RC, Solinsky MG, Cutrona KJ, Newton CL, Naylor-Olsen AM, McMasters DR, Krueger JA, Lewis SD, Lucas BJ, Kuo LC, Yan Y, Lynch JJ, Lyle EA.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):2062-6. PubMed ID: 18291642
    [Abstract] [Full Text] [Related]

  • 4. Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.
    Hanessian S, Therrien E, van Otterlo WA, Bayrakdarian M, Nilsson I, Fjellström O, Xue Y.
    Bioorg Med Chem Lett; 2006 Feb 15; 16(4):1032-6. PubMed ID: 16290930
    [Abstract] [Full Text] [Related]

  • 5. Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support.
    Brady SF, Stauffer KJ, Lumma WC, Smith GM, Ramjit HG, Lewis SD, Lucas BJ, Gardell SJ, Lyle EA, Appleby SD, Cook JJ, Holahan MA, Stranieri MT, Lynch JJ, Lin JH, Chen IW, Vastag K, Naylor-Olsen AM, Vacca JP.
    J Med Chem; 1998 Jan 29; 41(3):401-6. PubMed ID: 9464370
    [Abstract] [Full Text] [Related]

  • 6. Structure-based organic synthesis of unnatural aeruginosin hybrids as potent inhibitors of thrombin.
    Hanessian S, Ersmark K, Wang X, Del Valle JR, Blomberg N, Xue Y, Fjellström O.
    Bioorg Med Chem Lett; 2007 Jun 15; 17(12):3480-5. PubMed ID: 17428662
    [Abstract] [Full Text] [Related]

  • 7. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ, Almond HR, Hecker LR, Schott MR, Yabut SC, Zhang HC, Andrade-Gordon P, Corcoran TW, Giardino EC, Kauffman JA, Lewis JM, de Garavilla L, Haertlein BJ, Maryanoff BE.
    J Med Chem; 2005 Mar 24; 48(6):1984-2008. PubMed ID: 15771442
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and study on a novel inhibitor of thrombin containing no side chain at the P1 position of the polypeptide chain.
    Gershkovich AA, Kara DI, Kibirev VK.
    Semin Thromb Hemost; 1996 Mar 24; 22(4):343-5. PubMed ID: 8944419
    [Abstract] [Full Text] [Related]

  • 9. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
    Tucker TJ, Brady SF, Lumma WC, Lewis SD, Gardell SJ, Naylor-Olsen AM, Yan Y, Sisko JT, Stauffer KJ, Lucas BJ, Lynch JJ, Cook JJ, Stranieri MT, Holahan MA, Lyle EA, Baskin EP, Chen IW, Dancheck KB, Krueger JA, Cooper CM, Vacca JP.
    J Med Chem; 1998 Aug 13; 41(17):3210-9. PubMed ID: 9703466
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.
    Stürzebecher J, Prasa D, Hauptmann J, Vieweg H, Wikström P.
    J Med Chem; 1997 Sep 12; 40(19):3091-9. PubMed ID: 9301673
    [Abstract] [Full Text] [Related]

  • 11. Conformationally restricted analogs of the direct thrombin inhibitor FM 19.
    Girnys EA, Porter VR, Mosberg HI.
    Bioorg Med Chem; 2011 Dec 15; 19(24):7425-34. PubMed ID: 22055408
    [Abstract] [Full Text] [Related]

  • 12. The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors.
    Chirgadze NY, Sall DJ, Briggs SL, Clawson DK, Zhang M, Smith GF, Schevitz RW.
    Protein Sci; 2000 Jan 15; 9(1):29-36. PubMed ID: 10739244
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors: P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties.
    Semple JE, Rowley DC, Brunck TK, Ha-Uong T, Minami NK, Owens TD, Tamura SY, Goldman EA, Siev DV, Ardecky RJ, Carpenter SH, Ge Y, Richard BM, Nolan TG, Håkanson K, Tulinsky A, Nutt RF, Ripka WC.
    J Med Chem; 1996 Nov 08; 39(23):4531-6. PubMed ID: 8917639
    [No Abstract] [Full Text] [Related]

  • 14. Structure of a novel thrombin inhibitor with an uncharged D-amino acid as P1 residue.
    Friedrich R, Riester D, Göttig P, Thürk M, Schwienhorst A, Bode W.
    Eur J Med Chem; 2008 Jun 08; 43(6):1330-5. PubMed ID: 17950494
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures.
    Mai A, Massa S, Ragno R, Cerbara I, Jesacher F, Loidl P, Brosch G.
    J Med Chem; 2003 Feb 13; 46(4):512-24. PubMed ID: 12570373
    [Abstract] [Full Text] [Related]

  • 17. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.
    Tucker TJ, Lumma WC, Mulichak AM, Chen Z, Naylor-Olsen AM, Lewis SD, Lucas R, Freidinger RM, Kuo LC.
    J Med Chem; 1997 Mar 14; 40(6):830-2. PubMed ID: 9083470
    [No Abstract] [Full Text] [Related]

  • 18. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
    Slon-Usakiewicz JJ, Sivaraman J, Li Y, Cygler M, Konishi Y.
    Biochemistry; 2000 Mar 07; 39(9):2384-91. PubMed ID: 10694407
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors.
    Peifer C, Stoiber T, Unger E, Totzke F, Schächtele C, Marmé D, Brenk R, Klebe G, Schollmeyer D, Dannhardt G.
    J Med Chem; 2006 Feb 23; 49(4):1271-81. PubMed ID: 16480264
    [Abstract] [Full Text] [Related]

  • 20. Mechanism-based thrombin inhibitors: design, synthesis, and molecular docking of a new selective 2-oxo-2H-1-benzopyran derivative.
    Frédérick R, Robert S, Charlier C, Wouters J, Masereel B, Pochet L.
    J Med Chem; 2007 Jul 26; 50(15):3645-50. PubMed ID: 17580844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.